Research programme: MMP inhibitors - Millennium

Drug Profile

Research programme: MMP inhibitors - Millennium

Alternative Names: Matrix metalloprotease inhibitors research programme - Millennium; Matrix metalloproteinase inhibitors research programme - Millennium; MMP inhibitors research programme - Millennium; Research programme: matrix metalloprotease inhibitors - Millennium; Research programme: matrix metalloproteinase inhibitors - Millennium

Latest Information Update: 29 Nov 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Millennium Pharmaceuticals
  • Class
  • Mechanism of Action Matrix metalloproteinase inhibitors; Metalloprotease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Cardiovascular disorders; Inflammation

Most Recent Events

  • 29 Nov 2005 Discontinued - Preclinical for Cancer in USA (unspecified route)
  • 29 Nov 2005 Discontinued - Preclinical for Cardiovascular disorders in USA (unspecified route)
  • 29 Nov 2005 Discontinued - Preclinical for Inflammation in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top